South Florida, an area with the highest rate of HIV/AIDS in the country, is already starting to feel the effects of the Trump ...

The use of mobile health care units that distribute ART and PrEP medications increased uptake among people who inject drugs, ...

Georgia lawmakers are hoping to pass a bill before the legislative session ends Friday that would allow pharmacists to distribute HIV prevention medicines without a prescription, a policy change that ...

Overview of HIV Drugs MarketThe Global HIV Drugs Market is valued at USD 34.75 Billion in 2024 and is projected to reach a ...

Gilead Sciences (GILD) reachead $112.39 at the closing of the latest trading day, reflecting a +0.45% change compared to its last close.

In the most recent trading session, Gilead Sciences (GILD) closed at $111.88, indicating a +0.54% shift from the previous trading day.

Tomas Cihlar knew all too well that despite initial successes with combination treatment, HIV was firmly holding ground ...

Gilead Sciences (GILD) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some ...

On the same day the Trump Administration unceremoniously shut down the U.S. Department of Health and Human Services Regional ...

PEPFAR had been set to lead the rollout of Gilead Science's lenacapavir, which has been hailed as a "miracle" of HIV ...

The BRAIN Initiative — the full name is Brain Research Through Advancing Innovative Neurotechnologies — has been talked about ...